Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Palencia

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|October 2, 2013
Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature reviewAnn D Colosia, Roberto Palencia, Shahnaz Khan
Health and Quality of Life Outcomes|April 29, 2017
A review of patient-reported outcome measures to assess female infertility-related quality of lifeHelen Kitchen, Natalie Aldhouse, Andrew Trigg, et al.
Future Oncology (London, England)|September 8, 2021
Systematic literature review of current treatments for stage I-III Merkel cell carcinomaRoberto Palencia, Amrita Sandhu, Sarah Webb, et al.
Journal of Medical Economics|September 17, 2013
Modeling hard clinical end-point data in economic analysesAnuraag R Kansal, Ying Zheng, Roberto Palencia, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 2, 2015
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepirideCostel Chirila, Qingyao Zheng, Eric Davenport, et al.
Journal of Medical Economics|April 30, 2014
Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modelingVictoria K Brennan, Ann D Colosia, Catherine Copley-Merriman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 4, 2015
Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic reviewVictoria K Brennan, Josephine Mauskopf, Ann D Colosia, et al.
Cancer Reports (Hoboken, N.J.)|May 2, 2021
A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in TaiwanWen-Cheng Chang, Amy Y Lin, Jason C Hsu, et al.
Cancer Reports (Hoboken, N.J.)|August 28, 2023
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in TaiwanPo-Jung Su, Ying Xiao, Amy Y Lin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 12, 2006
The costs of planned cesarean versus planned vaginal birth in the Term Breech TrialRoberto Palencia, Amiram Gafni, Mary E Hannah, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|October 2, 2013
Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature reviewAnn D Colosia, Roberto Palencia, Shahnaz Khan
Health and Quality of Life Outcomes|April 29, 2017
A review of patient-reported outcome measures to assess female infertility-related quality of lifeHelen Kitchen, Natalie Aldhouse, Andrew Trigg, et al.
Future Oncology (London, England)|September 8, 2021
Systematic literature review of current treatments for stage I-III Merkel cell carcinomaRoberto Palencia, Amrita Sandhu, Sarah Webb, et al.
Journal of Medical Economics|September 17, 2013
Modeling hard clinical end-point data in economic analysesAnuraag R Kansal, Ying Zheng, Roberto Palencia, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 2, 2015
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepirideCostel Chirila, Qingyao Zheng, Eric Davenport, et al.
Journal of Medical Economics|April 30, 2014
Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modelingVictoria K Brennan, Ann D Colosia, Catherine Copley-Merriman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 4, 2015
Utility estimates for patients with Type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic reviewVictoria K Brennan, Josephine Mauskopf, Ann D Colosia, et al.
Cancer Reports (Hoboken, N.J.)|May 2, 2021
A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in TaiwanWen-Cheng Chang, Amy Y Lin, Jason C Hsu, et al.
Cancer Reports (Hoboken, N.J.)|August 28, 2023
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in TaiwanPo-Jung Su, Ying Xiao, Amy Y Lin, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|April 12, 2006
The costs of planned cesarean versus planned vaginal birth in the Term Breech TrialRoberto Palencia, Amiram Gafni, Mary E Hannah, et al.
Pageof 1